Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02151617 | A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649 | PHASE1 | COMPLETED | 40 | — | — | Jun 1, 2014 | Dec 1, 2014 | Jan 19, 2015 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Cohort 1-PF-06743649 or placebo | EXPERIMENTAL | Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3 |
| Cohort 2-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 3-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 4-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 5-PF-06743649 or placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06743649 | DRUG | 40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days |
| Placebo | DRUG | Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG...